|
and drug uptake into mammalian cells in vitro. Br J Cancer 1986; 54:
239-43.
33. Kawai K, Kamatani N, Georges E, Ling V. Identification of a membrane
glycoprotein overexpression in murine lymphoma sublines resistant to cis-
diamminedichloroplatinum (II). J Biol Chem 1990; 265: 13137-42.
34. Ishikawa T, Wright CD, Ishizuka H. GS-X pump Is functionally
overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia
HL-60 Cells and downregulated by cell differentiation. J Biol Chem 1994;
269: 29085-93.
35. Goto S, Yoshido K, MoriKawa T, Urata Y, Suzuki K,. Kondo T. Augmentation
of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer
cells. Cancer Res 1995; 55: 4297-301.
36. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R, Silvestrini R.
Expression of P-glycoprotein and in vitro or in vivo resistance
to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 1994;
30A: 1002-7.
37. Jedlitschky G, Leier J, Buchholz U, Barnouin K, Kurz G, Keppler D.
Transport of glutathione, glucuronate, and sulfate conjugates by the MRP
gene-encoded conjugate export pump. Cancer Res 1996; 56: 988-94.
38. Okuyama T, Maehara Y, Endo K, Baba H, Adachi Y, Kuwano M, Sugimachi K.
Expression of glutathione S-transferase-pi and sensitivity of human gastric
cancer cells to cisplatin. Cancer 1994; 74: 1230-6.
39. Awasthi S, Sharma R, Singhal SS, Herzog NK, Chaubey M, Awasthi YC.
Modulation of cisplatin cytotoxicity by sulphasalazine. Br J Cancer 1994;
70: 190-4.
40. Bongers V, Snow GB, Braakhuis BJM. The role of glutathione S-transferases
in head and neck squamous cell carcinogenesis. Eur J Cancer 1995; 31B: 349-
54.
41 Minagawa Y, Kigawa J, Ishihara H, Itamochi H, Terakawa N. Synergistic
enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-
11, for cisplatin-resistant HeLa cells. Jpn J Cancer Res 1994; 85: 966-71.
42. Boscia RE, Korbut T, Holden SA, Ara G, Teicher BA. Interaction of
topoisomerase I inhibitors with radiation in cis-Diamminedichloroplatinum
(II)-sensitive and -resistant cells in vitro and in the FSAIIC
fibrosarcoma in vivo. Int J Cancer 1993; 53: 118-23.
43. Kikuchi Y, Hirata J, Yamamoto K, Ishi K, Kita T, Kudoh K, Tode T, Nagata
I, Taniguchi K, Kuwano M. Altered expression of -glutamylcysteine
synthetase, metallothionein and topoisomerase I or II during acquisition of
drug resistance to cisplatin in human ovarian cancer cells. Jpn J Cancer Res
1997; 88: 213-7.
44. Hirata J, Kikuchi Y, Kita T, Imaizumi EE, Tode T, Ishii K, Kudoh K,
Nagata I. Modulation of sensitivity of human ovarian cancer cells to cis-
diamminedichloroplatinum (II) by 12-O-tetradecanoylphorbol-13-acetate and
D,L-Buthionine-S,R-Sulphoximine. Int J Cancer 1993; 55: 521-7.
45.Sugimoto C, Matsukawa S, Fujieda S, Noda I, Tanaka N, Tsuzuki H, Saito H.
Involvement of intracellular glutathione in induction of apoptosis by
cisplatin in a human pharyngeal carcinoma cell line. Anticancer Res 1996; 16:
675-80.
46. Pendyala L, Perez R, Weinstein A, Zdanowicz J, Creaven PJ. Effect of
glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a
human melanoma cell line. Cancer Chemother Pharmacol 1997, 40 (1): 38-44.
47. Kurokawa H, Nishio K, Ishida T, Arioka H, Fukuoka K, Nomoto T, Fukumoto
H, Yokote H, Saijo N. Effect of glutathione depletion on cisplatin
resistance in cancer cells transfected with the -glutamylcysteine
synthetase gene. Jpn J Cancer Res 1997; 88: 108-10.
48. Campling BG, Baer K, Baker HM, Lam YM. Cole SPC. Do glutathione and
related enzymes play a role in drug resistance in small cell lung cancer ctll
lines? Br J Cancer 1993; 68: 327-35.
49. Kodera Y, Akiyama S, Isobe K, Kondo K, Ito K, Yamauchi M, Takagi H.
Expression of -glutathione S-transferase gene (GSTP1) in gastric
cancer: lack of correlation with resistance against cis-
diamminedichloroplatinum (II). Eur J Cancer 1994; 30A: 2158-62.
50. Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug
chemosensitivity of human cervical squamous cell carcinoma cell lines with
intrinsic and acquired resistance to cisplatin. Br J Cancer 1993; 68: 240-50.
51. Eichholtz-Wirth H, Reidel G, Hietel B. Radiation-induced transient
cisplatin resistance in murine fibrosarcoma cells associated with elevated
metallothionein content. Br J Cancer 1993; 67: 1001-6.
52. Lazo JS, Basu A. Metallothionein expression and transient resistance to
electrophilic antineoplastic drugs. Semin Cancer Biol 1991; 2: 267-71.
53. Hishikawa Y, Abe SI, Kinugasa S, Yoshimura H, Monden N. Overexpression of
metallothionein correlates with chemoresistance to cisplatin and prognosis in
esophageal cancer. Oncology 1997; 54: 342-7.
54. Vaisman A, Vachenko M, Said I, Chaney SG. Cell cycle changes associated
with formation of Pt-DNA adducts in human ovarian carcinoma cells with
different cisplatin sensitivity. Cytometry 1997; 27: 54-64.
55. Hill BT, Scanlon KJ, Hansson J, Harstrick A, Pera M, Fichtinger-
Schepman AMJ, Shellard SA. Deficient repair of cisplatin-DNA adducts
identified in human testicular teratoma cell lines established from tumours
from untreated patients. Eur J Cancer 1994; 30A: 832-7.
56. Johnson SW, Swiggard PA, Handel LM, Godwin AK, Ozols RF, Hamilton TC.
Relationship between platinum-DNA adduct formation and removal and cisplatin
cytotoxicity in cisplatin-sensitive and resistant human ovarian cancer cells.
Cancer Res 1994, 54: 5911-6.
57. Turchi JJ, Li M, Henkels KM. Cisplatin-DNA binding specificity of calf
high mobility group I protein. Biochem 1996; 35: 2992-3000.
58.Ikeda S, Ozaki K. Action of mitochondrial endonuclease G on DNA damaged by
L-ascorbic acid, peplomycin, and cis-diamminedichloroplatinum (II). Biochem
Biophys Res Commun 1997, 235(2): 291-4.
59. Bissett D, McLaughlin K, Kelland LR, Brown R. Cisplatin-DNA damage
recognition proteins in human tumor extracts. Br J Cancer 1993; 67:742-8.
60. McLaughlin K, Coren G, Masters J, Brown R. Binding activities of cis-
platin-damage-recognition proteins in human tumor cell lines. Int J Cancer
1993; 53: 662-6.
61. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, Zee AG,
Anthoney DA. HMLN1 expression and cellular responses of ovarian tumor cells
to treatment with cytotoxic anticancer agents. Oncogene 1997, 15(1): 45-52.
62. Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N, Viano I,
Colangelo D, Leone R, Apostoli P, Cassinelli G, Gambetta RA, Zunino F.
Decreased drug accumulation and increased tolerance to DNA damage in tumor
cells with a low level of cisplatin resistance. Biochem Pharmacol 1998,
55(8): 1247-54.
63. Fishel R, Ewel A, Lescoe MC. Purified human MSH2 protein binds to DNA
containing mismatched nucleotides. Cancer Res 1994; 54: 5539-42.
64. Loeb LA. Microsatellite instability: marker of a mutator phenotype in
cancer. Cancer Res 1994; 54: 5059-63.
65. Chu G. Cellular responces to Cisplatin. J Biol Chem 1994; 269: 787-90.
66. Sorenson CM, Eastman A. Influence of cis-Diamminedichloroplatinum (II) on
DNA synthesis and cell cycle progression in excision repair proficient and
deficient hamster ovary cells. Cancer Res 1988; 48: 6703-7.
67. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Cisplatin
induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.
J Biol Chem 1998, 273 (36): 23419-25.
68. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is
associated with repair-mediated resistance to cis-diamminedichloroplatinum
(II). Cancer Res 1998, 58 (6): 1120-3.
69. Mestdach N, Pommery N, Saucier JM, Hecquet B, Founier C, Slomianny C,
Teissier E, Henichart JP. Chemoresistance to doxorubicin and cisplatin in a
murine cell line. Analysis of P-Glycoprotein, topoisomerase II activity,
glutathione and related enzymes. Anticancer Res 1994; 14: 869-74.
70. Kondo H, Kanzawa F, Nishio K, Saito S, Saijo N. In vitro and
in vivo effects of cisplatin and etoposide in combination on small cell lung
cancer cell lines. Jpn J Cancer Res 1994; 85: 1050-6.
71. Jong S, Timmer-Bosscha H, Vries EGE, Mulder NH. Effect of novobiocin on
cisplatin cytotoxicity and DNA interstrand cross-link formation in a
cisplatin-resistant, small-cell lung carcinoma cell line. Int J Cancer 1993;
53: 110-7.
72. Guchelaar H-J, Timmer-Bosscha H, Dam-Meiring A, Uges DRA, Oosterhuis JW,
Vries EGE Mulder NH. Enhancement of cisplatin and etoposide cytotoxicity
after all-trans retinoic-acid-induced cellular differentiation of a murine
embryonal carcinoma cell line. Int J Cancer 1993; 55: 442-7.
73. Seki S, Hongo A, Zhang B, Akiyama K, Sarker AH, Kudo T. Inhibition of
cisplatin-mediated DNA damage in vitro by ribonucleotides. Jpn J Cancer
Res 1993; 84: 462-7.
74. Parekh HK, Simpkins H. The differential expression of citokeratin 18 in
cisplatin-sensitive and -resistant human ovarian adenocarcinoma cells and its
association with drug sensitivity. Cancer Res 1995; 55: 5203-6.
75. Mirakhur B, Parekh HK, Simpkins H. Expression of the cisplatin
resistance phenotype in a human ovarian carcinoma cell line segregates with
chromosomes 11 and 16. Cancer Res 1996; 56: 2256-62.
76. Mueller H, Eppeberger U. The dual role of mutant p 53 protein in
chemosensitivity of human cancers. Anticancer Res 1996, 16 (6B): 3845-8.
77. Kawasaki t, Tomita Y, Bilim V, Takeda M, Takahashi K, Kumanishi T.
Abrogation of apoptosis induced by DNA-damaging agents in human bladder-
cancer cell lines with p 21/WAF1/CIP1 and/or p 53 gene alterations. Int J
Cancer 1996, 68 (4): 501-5.
78. Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J, Morimura T, Kaakaji
R, Peterson JW, Werbel B, Barnett GH. WAF1/CIP1 increases the susceptibility
of p 53 non-functional malignant glioma cells to cisplatin-induced apoptosis.
Oncogene 1996, 13 (6): 1279-85.
79. Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced apoptosis in
melanoma cells is p 53 dependent. Melanoma Res 1998, 8 (1): 17-23.
80. Biagosklonny MV, El-Deiry WS. Acute overexpression of wt p 53 facilitates
anticancer drug-induced death of cancer and normal cells. Int J Cancer 1998,
75 (6): 933-940.
81. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldginger
N, Pei H, Prokocimer M, Rotter V. Mutant p 53 protein interferes with p 53-
independent apoptotic pathways. Oncogene 1998, 16 (25): 3269-77.
82. Vasey PA, Jones NA, Jenkins S, Dive C, Broun R. Cisplatin, camptothecin,
and taxol sensitivities of cells with p 53-associated multidrug resistance.
Mol Pharmacol 1996, 50 (6): 1536-40.
83. Vikhanskaya F, Clerico L, Valenti M, Stazione NS, Broggini M, Parodi S,
Russo P. Mechanism of resistance to cisplatin in a human ovarian-carcinoma
cell line selected for resistance to doxorubicin: possible role of p 53. Int
J Cancer 1997, 72 (1): 155-9.
84. Vaisman A, Varchenko M, Said I, Chaney SG. Cell cycle changes associated
with formation of Pt-DNA adducts in human ovarian carcinoma cells with
different cisplatin sensitivity. Cytometry 1997, 27 (1): 54-64.
85. Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p 53
induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell
line. Cancer Res 1998, 58 (4): 698-703.
86. Ju JF, Banerjee D, Lenz HJ, Danenberg KD, Schmittgen TC, Spreas CP,
Schonthal AH, Manno DJ, Hochhauser D, Bertino JR, Danenberg PV. Restoration
of wild-type p 53 activity in p 53-null HL-60 cells confers multidrug
sensitivity. Clin Cancer Res 1998, 4 (5): 1315-22.
87. Fajac A, Da Silva J, Ahomadegbe JC, Rateau JG, Bernaudin JF, Riou G,
Benard J. Cisplatin-induced apoptosis and p 53 gene status in a cisplatin-
resistant human ovarian carcinoma cell line. Int J Cancer 1996, 86 (1): 67-
74.
88. Kondo S, Barna BP, Morimura T, Takeuchi J, Yuan J, Akbasak A, Barnett GH.
Interleukin-1-beta-converting enzyme mediates cisplatin-induced apoptosis in
malignant glioma cells. Cancer Res 1995, 55 (24): 6166-71.
89. De Feudis P, Debernardis D, Beccaglia P, Valenti M, Sire GE, Arzani D,
Stanzione S, Parodi S, D`Incalci M, Russo P, Broggini M. DDP-induced
cytotoxicity is not influenced by p 53 in nine human ovarian cancer cell
lines with different p 53 status. Br J Cancer 1997, 76 (4): 474-9.
90. Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. Expression of p
53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell
tumor cell lines. Br J Cancer 1998, 77 (10): 1562-7.
91. Ikeguchi M, Tatebe S, Kaibara N, Ito H. Changes in levels of expression
of p 53 and the product of the bcl-2 in lines of gastric cancer cells during
cisplatin-induced apoptosis. Eur Surg Res 1997, 29 (5), 396-402.
92. Pestell KE, Medlow CJ, Titley JC, Kelland LR, Walton MI. Characterisation
of the p 53 status, BCL-2 expression and radiation and platinum drug
sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer 1998,
77 (6): 913-8.
93. Nakata B, Chung KH, Ogawa M, Yanagawa K, Muguruma K, Inoue T, Yamashita
Y, Onoda N, Maeda K, Sawada T, Sowa. P 53 protein overexpression as a
predictor of the response to themotherapy in gastric cancer. Surg Today 1998,
28 (6): 595-8.
94. Petty R, Evans A, Duncan I, Kurbacher C, Cree I. Drug resistance in
ovarian cancer – the role of p 53. Payhol Oncol Res 1998, 4 (2): 97-102.
95. Simonian PL, Grillot DA, Andrews DW, Leber B, Nunez G. Bax
homodimerization is not required for Bax to accelarate chemotherapy-induced
cell death. J Biol Chem 1996, 271 (50): 32073-7.
96. Liu JR, Fletcher B, Page C, Hu C, Nunez G Baker V. Bcl-xL is expressed in
ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol
1998, 70 (3), 398-403.
97. Miyake H. Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Eto H,
Gohji K, Arakawa S, Kamidono S, Saya H. Overexpression of Bcl-2 in bladder
cancer inhibits apoptosis induced by cisplatin and adenoviral-mediated p 53
gebe transfer. Oncogene 1998, 16 (7): 1933-43.
98. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xl can confer
a multidrug resistance phenotype. Blood 1995, 86 (5): 1903-10.
99.Simonian PL, Grillot AM, Nunez G. Bcl-2 and Bcl-Xl can differentially
block chemotherapy induced cell death. Blood 1997, 90 (3): 1208-16.
100. Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C. Cisplatin- and
paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship
between bax and bak up-regulation and the functional status of p 53. Mol
Pharmacol 1998, 53 (3): 819-26.
101. Boersma AW, Nooter K, Burger h, Kortland CJ, Stoter G. Bax upregulation
is an early event in cisplatin-induced apoptosis in human testicular germ-
cell tumor cell line NT2, as quantitated by flow cytometry. Cytometry 1997,
27 (3): 275-82.
102. Lee JU, Hosotani R, Wada H, Doi R, Kosiba T, Fujimoto K, Miyamoto Y,
Mori C, Nakamura N, Shiota K, Imamura M. Mechanism of apoptosis induced by
cisplatin and VP-16 in PANC-1 cells. Anticancer Res 1997, 17 (5A): 3445-50.
103. Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, Bosl GJ,
Chaganti RS. Human male germ cell tumor resistance to cisplatin is linked to
TP53 gene mutation. Oncogene 1998, 16 (18): 2345-9.
104. Sakahura C, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S, Tsujimoto
H, Imanishi T, Ogaki M, Yamazaki J, Hagiwara A, Yamaguchi T, Sawai K,
Takahashi T. Overexpression of bax sensitizes breast cancer MCF-7 cells to
cisplatin and etoposide. Surg Today 1997, 27 (7): 676-9.
105. Kondo S, Shinomura Y, Kanayama S, Higashimoto Y, Kiyohara T, Zushi S,
Kitamura S, Ueyama H, Matsuzawa Y. Modulation of apoptosis by endogenous Bcl-
Xl expression in MKN-45 human gastric cancer cells. Oncogene 1998, 17(20):
2585-91.
106. Nakata B, Muguruma K, Hirakawa K, Chung YS, Yamashita Y, Inoue T,
Matsuoka T, Onoda N, Kato Y, SowaM. Predictive value of Bcl-2 and Bax protein
expression for chemotherapeutic effect in gastric cancer. Apilot study. Oncol
1998, 55(6): 543-7.
107. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo
H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S, Saito H, Johnston
PG. Biological markers as a predictor for response and prognosis of
unresectable gastric cancer patients treated with 5-fluorouracil and cis-
platinum. Clin Cancer Res 1998, 4 (6): 1469-74.
108. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The
prognostic significance of bcl-2 and p 53 expression in ovarian carcinoma.
Cancer Res 1996, 56 (9): 2178-84.
109. Muguruma K, Nakata B, Hirakawa K, Yamashita Y, Onoda N, Inoue T,
Matsuoka T, Kato Y, Sowa. P 53 and Bax protein expression as predictor of
chemotherapeutic effect in gastric carcinoma. Gan To Kagaku Ryoho 1998, 3:
400-3.
110. Ferguson AW, Flatow U, MacDonald NJ, Larminat F, Bohr VA, Steeg PS.
Increased sensitivity to cisplatin by nm23-transfected tumor cell lines.
Cancer Res 1996; 56: 2931-5.
111.Masumoto N, Nakaano S. Cell signalling and CDDP resistance. Gan To Kagaku
Ryoho 1997, 24(4): 424-30.
112. Demidova NS, Ilynskaya GV, Shiryaeva OA, Chernova OB, Goncharova SA,
Kopnin BP. Decreased sensitivity of multidrug-resistant tumor cells to
cisplatin is correlated with sorcin gene co-amplification. Neoplasma 1995;
42: 195-201.
Страницы: 1, 2, 3, 4
|
